Find and Join

News Logo

• Tattoos, legal counsel, and good info

  If APC had a tattoo on its bicep — if we had a bicep, I mean — it might well read “Consult legal counsel.” read more →

• State advocacy update

  APC sent a letter to the New Mexico Board of Pharmacy this week commenting on its proposed amendments that would align the state with USP (good), but would also require that pharmacists ensure all flavors are inert (yikes). read more →

• Board approves new officer succession

  The APC Board of Directors has voted to name Gina Besteman (previously vice president) the board chair-elect after the resignation of Michelle Moser from the position. Besteman will assume the chair in January 2025. read more →

• FDA is concerned about compounded GLP-1 dosing errors

  Earlier this week APC received a letter from the FDA explaining the agency's concerns regarding dosing and patient usage of compounded semaglutide and tirzepatide. read more →

• Did you get your Compounding Pharmacy Snapshot?

  If you haven’t already, don’t forget to download and share the 2023-2024 edition of our Snapshot of Pharmacy Compounding in America. read more →

• After report, FTC to sue PBMs

  On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs. read more →

More News

PCCA Ad

Blank

Medisca Ad

Blank

Fagron Ad

Blank

Wedgewood Ad

Blank

TopiClick Ad

We’ve been bugging the California Board of Pharmacy (politely!) for a while, trying to get a statement on its position and enforcement posture regarding the compounding of FDA-approved drugs that are currently in shortage. There has been some confusion — mixed messages, you might say — coming out of the Golden State regarding how the BoP views GLP-1 compounding, and we wanted some official clarification.

Good things, apparently, come to those who wait. In this case, it’s a response from the board in a letter last week saying that, “In general, the Board does try to align with FDA when possible,” and also reminding us that compounding pharmacies “must comply with a myriad of state and federal laws.” The bottom line, though — and our take on the letter (you can read it here) — is that the CA BoP’s position on GLP-1 compounding is consistent with that of FDA. 

APC will soon be releasing a best practices document related to shortage drug compounding, including GLP-1s, that tracks to law, FDA guidance, and USP standards … and also recommends certain testing and other measures that go beyond those standards. Stay tuned.